Received Mar 26, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | UNK | 947357 | IM / LA |
The provider contacted the patient?s mother to discuss possible side effects following administration of the hepatitis B (adolescent dose) vaccine. It was explained that while mild side effects such as soreness at the injection site or low-grade fever can occur, no severe adverse events were expected. No specific symptoms, signs, or adverse reactions were reported in this case, and no treatment was required. The outcome was uneventful, with no severe side effects occurring after vaccination.
N/A
N/A
N/A
N/A
n/a